Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Dow
Merck
Express Scripts
Mallinckrodt

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR AMIFOSTINE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Amifostine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002643 ↗ Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor Completed Children's Cancer Group Phase 2 1995-04-01 Phase II trial to study the effectiveness of combination chemotherapy in treating patients with newly diagnosed metastatic Ewing's sarcoma or primitive neuroectodermal tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
NCT00002643 ↗ Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor Completed National Cancer Institute (NCI) Phase 2 1995-04-01 Phase II trial to study the effectiveness of combination chemotherapy in treating patients with newly diagnosed metastatic Ewing's sarcoma or primitive neuroectodermal tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
NCT00003048 ↗ Amifostine in Treating Patients With Myelodysplastic Syndrome Completed National Cancer Institute (NCI) Phase 2 1997-06-05 RATIONALE: Amifostine may improve blood counts in patients with myelodysplastic syndrome. PURPOSE: Phase II trial to study the effectiveness of amifostine in treating patients with myelodysplastic syndrome.
NCT00003048 ↗ Amifostine in Treating Patients With Myelodysplastic Syndrome Completed M.D. Anderson Cancer Center Phase 2 1997-06-05 RATIONALE: Amifostine may improve blood counts in patients with myelodysplastic syndrome. PURPOSE: Phase II trial to study the effectiveness of amifostine in treating patients with myelodysplastic syndrome.
NCT00003068 ↗ High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer Completed University of Arizona Phase 2 1997-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose mitoxantrone, thiotepa, and cyclophosphamide plus autologous peripheral stem cell transplantation and amifostine in treating patients with primary, locally advanced, or stage IV breast cancer.
NCT00003072 ↗ Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer Completed University of California, San Francisco Phase 2 1997-05-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more tumor cells. PURPOSE: Randomized phase II double-blinded trial to study the effectiveness of paclitaxel and carboplatin given with either amifostine or placebo in patients with metastatic stage III or stage IV ovarian cancer or metastatic stage III or stage IV non-small cell lung cancer.
NCT00003089 ↗ Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer Completed Sidney Kimmel Cancer Center at Thomas Jefferson University Phase 2 1997-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel, carboplatin, amifostine, and radiation therapy in treating patients who have unresectable locally advanced or partially resected non-small cell lung cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Amifostine

Condition Name

Condition Name for Amifostine
Intervention Trials
Drug/Agent Toxicity by Tissue/Organ 19
Head and Neck Cancer 16
Lung Cancer 14
Radiation Toxicity 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Amifostine
Intervention Trials
Drug-Related Side Effects and Adverse Reactions 19
Head and Neck Neoplasms 17
Lung Neoplasms 12
Radiation Injuries 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Amifostine

Trials by Country

Trials by Country for Amifostine
Location Trials
United States 362
Canada 27
France 8
Australia 6
China 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Amifostine
Location Trials
California 20
Illinois 18
Pennsylvania 16
Ohio 15
Florida 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Amifostine

Clinical Trial Phase

Clinical Trial Phase for Amifostine
Clinical Trial Phase Trials
Phase 4 4
Phase 3 11
Phase 2/Phase 3 1
[disabled in preview] 70
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Amifostine
Clinical Trial Phase Trials
Completed 52
Unknown status 15
Terminated 10
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Amifostine

Sponsor Name

Sponsor Name for Amifostine
Sponsor Trials
National Cancer Institute (NCI) 33
MedImmune LLC 10
Dana-Farber Cancer Institute 6
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Amifostine
Sponsor Trials
Other 89
NIH 33
Industry 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Mallinckrodt
Dow
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.